User login
Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).
Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).
Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.
Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.
Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9
Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).
Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).
Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.
Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.
Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9
Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).
Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).
Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.
Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.
Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9